Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 13/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581337 | 0.90 | HDAC2 (0.74) | HDAC2HDAC1HDAC3KCNH2HDAC8 | |
| SCHEMBL4578619 | 0.90 | KCNH2 (0.73) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL4580101 | 0.89 | HDAC2 (0.64) | HDAC2HDAC1HDAC3KCNH2HDAC4 | |
| SCHEMBL4579230 | 0.87 | HDAC1 (0.65) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL4579437 | 0.87 | HDAC2 (0.61) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL3111008 | 0.86 | HDAC1 (0.74) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL4578885 | 0.86 | HDAC2 (0.67) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL1640304 | 0.85 | HDAC1 (0.80) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL4580625 | 0.85 | HDAC1 (0.61) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL4580031 | 0.85 | HDAC2 (0.61) | HDAC2HDAC1HDAC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | claimed |
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| WO-2009033281-A1 | CANCER COMBINATION THERAPY WITH A SELECTIVE INHIBITOR OF HISTONE DEACETYLASE HDAC1, HDAC2 AND/OR HDAC3 AND A MICROTUBULE STABILIZER | METHYLGENE INC. (CA) | 2009-03-19 | — | — | WO | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC2 5/4885HDAC1 1/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.